Transaction Overview - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025, for the acquisition of a Class 1 new Chinese medicine "Chaiqin Ning Shen Granules" for RMB 22 million [2] - This transaction does not constitute a related party transaction and falls within the chairman's authorization scope, thus does not require board or shareholder approval [2] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is one of the earliest TCM research institutions in China, integrating medical care, research, teaching, and industry [3] - The institute has undertaken over 1,033 research projects and has received numerous awards, including 15 national new drug approvals and 31 authorized invention patents [3] Target Transaction Details - The transfer includes the clinical trial approval notice and related patents for "Chaiqin Ning Shen Granules" [4] - The granules are indicated for liver qi stagnation and anxiety-related insomnia, showing significant improvement in symptoms [5] Market Context - According to a report by the China Sleep Research Society, 48.5% of adults in China experience sleep difficulties, with a growing prevalence of insomnia-related anxiety [6] - The insomnia medication market in China grew from RMB 9.84 billion in 2016 to RMB 11.7 billion in 2020, with projections of RMB 15.12 billion and RMB 21.19 billion by 2025 and 2030, respectively [6] Agreement Details - The agreement stipulates that the company will pay a total of RMB 22 million, with payments tied to specific milestones in the drug development process [12] - The agreement includes provisions for the transfer of all relevant technical materials and responsibilities for both parties in the development process [8][9] Impact on the Company - The acquisition of the clinical trial approval and patent rights for "Chaiqin Ning Shen Granules" is expected to enhance the company's R&D pipeline for innovative Chinese medicines, improving its core competitiveness and sustainable development [16] - The agreement's implementation may take time, and it is not expected to have a significant short-term impact on the company's operating performance [16]

Regulatory Changes - The National Health Commission has issued a notice prohibiting medical institutions from using misleading names for outpatient services that imply efficacy, emphasizing the need for clear and accurate naming practices [1] Drug Procurement - The National Medical Insurance Administration announced that 480 pharmaceutical companies are competing in the 11th batch of national drug procurement, with 55 drugs proposed for inclusion, averaging 15 companies per drug, and some drugs having over 40 participating companies [2] Legal Actions Against Fraud - The Supreme People's Court reported a significant increase in the prosecution of medical insurance fraud cases, with 1,156 cases involving 2,299 individuals concluded in 2024, marking a 131.2% year-on-year increase and recovering over 402 million yuan in lost funds [3] Drug Approvals - Innovent Biologics announced that its oral GLP-1R agonist IBI3032 has received FDA approval for clinical trials, with plans to initiate Phase I trials in mid-2025 targeting overweight or obese individuals [4] - Dyne Therapeutics received breakthrough therapy designation from the FDA for its investigational therapy DYNE-251 for Duchenne muscular dystrophy, with data expected by the end of 2025 [5] - Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, has received a drug registration certificate for Finasteride tablets, which are included in the national medical insurance drug list [6][7] Mergers and Acquisitions - Shanghai TuoJing announced the acquisition of 82% of Wuhan Kanglu Biological for 328 million yuan, focusing on advancements in molecular diagnostics [8] Financial Performance - Jiuzhou Pharmaceutical reported a 3.86% increase in revenue to 2.871 billion yuan and a 10.7% increase in net profit to 526 million yuan for the first half of 2025 [10] Strategic Investments - Yabao Pharmaceutical plans to acquire a traditional Chinese medicine project for 22 million yuan, enhancing its R&D pipeline and competitive edge [11] Shareholder Actions - Chenshin Pharmaceutical announced that a major shareholder plans to reduce their stake by up to 3% through market transactions, which is not expected to significantly impact the company's governance or operations [12]

Transaction Overview - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute for the new Chinese medicine project "Chaiqin Ning Shen Granules" for a total of RMB 22 million [2][16] - The agreement includes the clinical trial approval, patent rights, and related technical materials for the drug [2][4] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is a leading institution in TCM research and has received numerous accolades and approvals for its contributions to the field [3] - The institute has undertaken over 1,033 research projects and has been recognized with multiple provincial and national awards [3] Product Details - The product "Chaiqin Ning Shen Granules" is classified as a Category 1.1 new drug and is designed to treat insomnia and anxiety symptoms [4][5] - The drug received clinical trial approval from the National Medical Products Administration in January 2025 [5] Agreement Details - The agreement stipulates that the company will pay the total amount of RMB 22 million based on milestone achievements related to the drug's development [6][11] - The payment structure includes specific amounts tied to the completion of various stages of clinical trials and regulatory approvals [12] Impact on the Company - The acquisition of the new drug's clinical trial approval and patent rights is expected to enhance the company's R&D pipeline and improve its competitive edge in the market [16] - The company aims to expedite the development of new products, aligning with its strategic goals and benefiting shareholders [16]

Transaction Overview - Company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025, for the acquisition of a new TCM drug "Chaiqin Ning Shen Granules" for RMB 22 million [1][2] - The transaction does not constitute a related party transaction and falls within the chairman's authorization [1][2] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is a leading TCM research institution in China, involved in medical, research, teaching, and industrial activities [1][2] Target Asset Details - The target asset includes the clinical trial approval notice and related patents for "Chaiqin Ning Shen Granules," which is classified as a TCM Class 1.1 drug [2][3] - The drug is indicated for insomnia with anxiety symptoms, showing significant improvement in related symptoms [2][3] Market Context - According to the 2025 China Sleep Health Survey, 48.5% of adults experience sleep disturbances, with a growing prevalence among older adults [2] - The insomnia medication market in China grew from RMB 9.84 billion in 2016 to RMB 11.7 billion in 2020, with projections of RMB 15.12 billion and RMB 21.19 billion by 2025 and 2030, respectively [2][3] Agreement Details - The agreement includes provisions for the transfer of clinical trial data, patents, and technical support from the counterparty to the company [3][4] - Payment is structured based on milestone achievements, totaling RMB 22 million, with specific amounts tied to the completion of clinical trials and regulatory approvals [5][6] Impact on Company - The acquisition of "Chaiqin Ning Shen Granules" is expected to enhance the company's TCM innovation pipeline, accelerate new product development, and improve competitive advantage [6][7] - The agreement is anticipated to have a long-term positive impact on the company's growth strategy, although short-term effects on financial performance are not expected [6][7]

Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine project, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025 [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine new drug "Chaiqin Ning Shen Granules" for RMB 22 million [1] Group 2: Strategic Implications - The acquisition of the clinical trial approval and patent rights is expected to facilitate the rapid expansion of the company's traditional Chinese medicine R&D pipeline [1] - This move aligns with the company's development strategy and is in the interest of all shareholders [1] Group 3: Impact on Financial Performance - The agreement's implementation timeline is lengthy, and it is noted that there will be no significant short-term impact on the company's operating performance [1]

Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - On August 4, 2025, the company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the Class 1 new drug "Chaiqin Ning Shen Granules" for a total of 22 million RMB [1] - This transaction does not constitute a related party transaction and does not require approval from the board of directors or shareholders [1] Group 2: Strategic Implications - The acquisition is expected to facilitate the rapid expansion of the company's pipeline for innovative traditional Chinese medicine [1] - It aims to accelerate the development of new products, thereby enhancing the company's core competitiveness and sustainable development capabilities [1] - The transaction aligns with the company's development strategy and benefits all shareholders [1] Group 3: Financial Impact - The transaction is not expected to have a significant impact on the company's operating performance in the short term [1]

人民财讯8月5日电，亚宝药业(600351)8月5日晚间公告，公司于8月4日与山西省中医药研究院（简 称"山西省中医院"）签署了中药新药项目技术转让协议。公司以2200万元受让山西省中医院拥有的中药 1.1类新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 转自：证券时报 ...

格隆汇8月5日丨亚宝药业(600351.SH)公布，公司于2025年8月4日与山西省中医药研究院（称"山西省中 医院"）签署了中药新药项目技术转让协议（称"协议"）。公司以人民币2200万元受让山西省中医院拥 有的中药1.1类新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 ...

公司本次受让中药创新药柴芩宁神颗粒临床试验批件和发明专利等相关技术，有利于公司快速拓展公司 中药创新药研发管线，加快公司新产品研发进度，提高公司的核心竞争力和可持续发展能力，符合公司 的发展战略以及全体股东的利益。本次协议签订后，因各事项的推进时间较长,存在不确定性，短期内 不会对公司经营业绩产生重大影响。 亚宝药业（600351）(600351.SH)发布公告，公司于2025年8月4日与山西省中医药研究院(简称"山西省中 医院")签署了中药新药项目技术转让协议。公司以人民币2200万元受让山西省中医院拥有的中药1.1类 新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 ...